Well you see some of it...$18 in 2015 from here is a nice return. But if you look at comparables in the M2M business with ESYS's growth and profitability - the 1 year target should be in the mid-20's. The takeout value today is even higher. The main problem with this company is that the share float is too small. I wouldn't be surprised to see a $10 million+ offering in the near future - I think it would actually benefit the share price. A split might also been beneficial at some point. Anyway - if management continues to deliver on growth and product offerings, I could easily see the market cap reaching $200 - $400 million over the next few years - from the current $40 million.
The after hours activity (low volume) and the lack of news today make me think this action is a newsletter pump & dump...unfortunately.
I appreciate the entry level in the $12's...I'm half way where I want to be on this investment. I wouldn't mind getting the rest a little lower, if you don't mind. Congrats to those who got in at sub $4 and sub $8 over the past year and a half. I wouldn't mind a little dip to the $8's between now and year end - that would still be a double for you $4 investors - don't be greedy.
Thank you for your attention to this matter.
I think people here are dead wrong about the equity offerings DO has done - I don't think he had a choice back in October when the company had no cash at all and he got the best pricing he could. If he didn't do the follow on when he did, the company would have $10 million or less in the bank and be looking at a near future capital raise at $2 or less - the market has proven him right.
Now the failure to strike better deals on the licensing and trials is either a problem with DO or the technology - I don't know the answer and from what I can tell - no one on this board is sure about the technology. Advaxis has clearly not proven it so far, and it's going to take $ and brains to do that.
The problem is the charts look terrible - more like a retest of $280 - and the general market sentiment is going to work against AMZN over the near term. pretty strong support at $312 though...but once that breaks, its going to be a hard, fast drop.
There is no economic value in this company remaining independent, consolidation in the M2M industry is needed, and management is already being changed out. A sale would be in the best interest of all parties.
The Market might start looking at global risks...
I'm hoping the management team makes a fortune on those RSUs. The share price wouldn't be any better if the company didn't raise cash when it did. The new management team needs to execute and get rewarded for their efforts. Small biotechs are very rarely a buy and hold. They are ALWAYS a gamble. Unfortunate for long term investors.
Last quarter was great-I thought is was going to be much tougher. ESYS is well positioned in a market that is set to boom - and management is executing.
This is one of those companies that could easily be a multi-multi-multi-bagger for investors who get in early and hold. It's off of all radars right now - but won't be for long. When they reach a size where institutional money can invest...fuggedaboutit....
and the rest of the paragraph states:
"While Kaeser [Siemens' CEO] declined to comment on potential targets, process automation offerings for the gas and oil industry are “a desired area to acquire,” he said, CITING TECHNOLOGY AROUND LIQUIFIED NATURAL GAS."
TDW estimated to grow earnings 30%. Selling at 14.8 times TTM earnings and 11 times 2015 earnings and 1.1 times book value. Not sure what's holding the valuation back...also not sure why management doesn't put some of the $200 million share buy back plan to use.
It's worth listening to the Investor/Analyst day webcast on their website. The do a good job of laying out their opportunities in various markets, the recent capacity expansions and at the end discuss their strategy of short term gross margins vs. long term market share in their rapidly expanding markets. Definitely a good long term Buy. They are well positioned to continue their remarkable growth.